The ESSENCE trial will provide valuable data on the maintenance of histological benefits over 240 weeks of continuous treatment, but long-term extension studies and off-treatment follow-up protocols are needed to characterize rebound kinetics
Researchers have already tested a range of doses and escalation schedules, providing valuable insight into how treatment may start, increase, and be maintained
They deserve accurate information, which is why this article exists: not to sell you a competing product, but to lay out what the science actually says so you can make an informed choice
For example, at the time of the study, of those using GLP - 1 drugs for longer than one year, more than three-quarters said they were using the drug for health management, and less than one-quarter for weight loss
In the 24-week LIVE trial in people with stable chronic HF (with or without diabetes), liraglutide did not meaningfully improve LV EF or other variables including quality of life (Jorsal et al., 2017)
Im bullish on humanity